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Abstract The cholesterol-containing complexes in the urine 
of normal subjects and patients with diseases accompanied by 
hyperexcretion of urinary cholesterol were characterized. In 
normal subjects, the major portion of the recovered urinary 
cholesterol was eluted in the void volume fractions after gel 
chromatography on Bio-Gel A-5m; this suggested an association 
with a macromolecular complex above 5 X 1 O6 daltons. A com- 
parable elution pattern was seen in most of the urines of the 
patients with benign or malignant diseases of the kidneys or the 
urogenital tract. However, in single patients with hyperexcretion 
of urinary cholesterol, considerable amounts of cholesterol were 
detected in the included volume of the column. This was caused 
by additional excretion of high density lipoproteins or both high 
and low density lipoproteins in the urine which could be iden- 
tified in these fractions by agarose electrophoresis and immu- 
nodiffusion. These results indicate that the macromolecular 
complex represents the majority of the recovered urinary cho- 
lesterol in normal subjects and in disease states with known 
hyperexcretion. Macroscopically, the isolated cholesterol-con- 
taining complex in the void volume fractions was turbid, and 
electron microscopy showed lipoprotein-like particles with di- 
ameters ranging from 300 to 700 A. The chemical analysis 
revealed median values of protein (46.0%), triglycerides (1 6.3%), 
cholesterol (8.2%), and phospholipids (29.5%) in normal subjects 
and comparable results in the patients with benign or malignant 
diseases of the kidney and the urogenital tract. Ethanolamine 
glycerophospholipids, phosphatidylcholine, sphingomyelin, and 
phosphatidylserine were the main phospholipid components. 
After ultracentrifugation in a CsCl gradient, the cholesterol- 
containing complex was found between densities 1.1 and 1.3 
g/ml. By SDS polyacrylamide electrophoresis, up to 17 protein 
subunits in the molecular weight range of 14,000 to 87,500 
were separated. Immunodiffusion studies showed in about 40% 
precipitin lines against anti-human albumin, but no reactions 
against anti-human apoHDL and anti-human apoLDL. However, 
immunodiffusion of the macromolecular complex against anti- 
liver-specific and anti-kidney-specific lipoproteins revealed single 
precipitin 1ines.M In conclusion, the isolated cholesterol-con- 
taining urinary complex showed many characteristics of mem- 
brane-associated protein-lipid particles of the human kidney and 
even the liver. These proteolipids are the major source of urinary 
cholesterol in normal and disease states. They could be derived 
partially from the kidney, but in addition possibly from other 
parts of the urogenital system, especially the bladder.-Jiingt, 
D., H. Weisn, E. Siear, and H. J. Karl. Urinary cholesterol: 
its association with a macromolecular protein-lipid complex. J. 
Lipid Res. 1984. 25: 655-664. 
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Small amounts of cholesterol, mainly nonesterified, are 
present in normal urine (1-7), whereas elevated levels 
have been reported in patients with benign and malignant 
diseases of the kidney and the urogenital tract (8-27). 
On the basis of ultrafiltration studies, excretion as a pro- 
tein-bound complex has been suggested (28). In normal 
urine most of the cholesterol seems to be associated with 
a light particulate fraction, similar to plasma membranes 
(29). However, in patients suffering from the nephrotic 
syndrome, a urinary loss of plasma high density (HDL) 
and in some cases also of low density (LDL) lipoproteins 
has been reported (30, 31). 
It was the aim of this study to characterize the cho- 
lesterol-containing complexes in the urine of normal sub- 
jects and in disease states with known hyperexcretion. 
We demonstrate that cholesterol in the urine is associated 
mainly to a macromolecular protein-lipid complex which 
might be of cellular origin. In addition, in some cases 
HDL and LDL could be identified, especially in patients 
with the nephrotic syndrome. 
MATERIALS AND METHODS 
Normal subjects and collection of urine 
The group of normal subjects included four men and 
five women, 18 to 46 years old, who had no history or 
clinical or biochemical signs of a renal or urogenital dis- 
ease. Microscopic examination of the urine samples was 
normal, as well as the results of the N-Multistix reagent 
strips for protein, glucose, bilirubin, blood cells, ketone 
Abbreviations: HDL, high density lipoprotein; LDL, low density 
lipoprotein; VLDL, very low density lipoprotein; GLC, gas-liquid 
chromatography; SDS-PAGE, sodium dodecyl sulfate polyacrylamide 
gel electrophoresis; LSP, liver-specific lipoprotein; KSP, kidney-specific 
lipoprotein; TLC, thin-layer chromatography. 
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bodies, nitrate, and urobilinogen. The  concentrations of 
creatinine and total protein in serum were normal in all 
cases and the excretion of urinary protein was below 100 
mg/24 hr (Table 1). During the collection period of 24 
hr the urine was kept refrigerated (4°C) and sodium azide 
(0.02%) was added to prevent bacterial growth. Frac- 
tionation of urinary cholesterol started within 1 hour 
after the end of the collection period. 
Patients 
The group of patients consisted of 12 with benign and 
9 with malignant diseases of the kidney or the urogenital 
tract. Diagnoses were established by routine clinical pro- 
cedures including urinary protein quantitation, intrave- 
nous pyelography, cystoscopy, renal ultrasound, and his- 
tological examination of biopsies or resected material. 
Further clinical data of these patients including protein 
and creatinine in serum and 24-hr excretion of protein 
in the urine are given in Tables 2 and 3. 
Fractionation of urinary cholesterol 
For fractionation of urinary cholesterol usually the 
whole 24-hr urine volumes were used, and were passed 
through a Selecta filter no. 1 1 17 1/2 (Schleicher Schull). 
This filtration removes larger particles (5-10 pm in di- 
ameter) such as intact cells and larger cellular debris. 
After filtration NaCl was added to the urinary samples 
(final concentration 0.56 M) to precipitate the Tamm- 
Horsefall mucoprotein (32). This was removed by cen- 
trifugation (8000 rpm for 10 min) and the supernatant, 
considered as the upper 90% of the volume, was collected. 
Recovery studies of urinary cholesterol in single specimens 
revealed a loss of - 10% during these procedures. Ul- 
trafiltration was done in a stirred cell (Amicon model 
402 and Amicon model 52) using PM 10 membranes at 
4°C to a final volume of 3-5 ml. This concentration step 
was the most critical in regard to the loss of urinary cho- 
lesterol since some of the lipid perhaps adhered to the 
PM 10 membranes or might even pass the membrane. 
Aliquots of 2-3 ml of the concentrated urine were used 
for gel chromatography on a 1.2 m X 2.0 cm Bio-Gel 
A-5 m column (BioRad), mesh 200-400, according to 
Sata, Havel, and Jones (33). Elution was performed with 
0.15 M NaCl in water containing 0.01 M EDTA and 
0.02% NaNs at pH 7.0. Usually 48 to 50 fractions (8.5 
ml) were collected. Absorbance at 280 nm was determined 
in a spectrophotometer (Beckman, model 24). 
gradient ultracentrifugation, immunodiffusion, agarose 
electrophoresis, and SDS-polyacrylamide gel electropho- 
resis. Cholesterol-containing fractions in the included 
volume of the column were studied separately by agarose 
electrophoresis and immunodiffusion. A considerable 
amount of urinary cholesterol was lost as a consequence 
of the different fractionation procedures, especially the 
two ultrafiltration steps. Recovery studies in single urinary 
specimens for cholesterol showed a total loss of urinary 
cholesterol between 30 and 50% at the end of the second 
ultrafiltration. 
Chemical assays 
Total cholesterol was analyzed in 1.0-ml aliquots of 
the 24-hr urine collection and the 8.5-ml fractions after 
gel chromatography. After extraction with 8 ml of chlo- 
roform-methanol 3:l (v/v) and centrifugation, 5 ml of 
chloroform was removed and dried under a stream of 
nitrogen. The residue was hydrolyzed with 0.5 ml of 
ethanolic KOH at 60°C for 60 min and reextracted with 
6 ml of n-hexane and evaporated. The  residue from 5 
ml of the extract was dissolved in 0.1 ml of the internal 
standard solution (1 0 mg of androstendione/dl of isooc- 
tane). Gas-liquid chromatographic determination of cho- 
lesterol was performed using a 1.8 X 2 mm, 1% XE 60 
column, column temperature 220"C, with flame ioniza- 
tion detectors. 
Triglycerides were measured enzymatically with com- 
mercial test kits (Boehringer Mannheim) (34). 
Phospholipids in the lipid extracts (chloroform-meth- 
anol 3: 1, v/v) were determined by phosphorus analysis 
(35). The  phospholipids were fractionated by TLC on 
20 X 20 cm glass plates coated with silica gel (Merck). 
After two-dimensional TLC in the solvent systems chlo- 
roform-methanol-25% aq. ammonia 60:20:5 and chlo- 
roform-acetone-methanol-acetic acid-water 3:4: 1 : 1 :0.5, 
the separated phospholipids were made visible with iodine 
vapor; they were individually recovered and assayed for 
phosphorus content (36). 
Protein was measured by the method of Kashyap, 
Hynd, and Robinson (37). 
Electron microscopy 
Electron microscopy was performed with a Siemens 
Typ 101 instrument and a negative staining tech- 
nique (38). 
Total cholesterol was measured by gas-liquid chro- 
matography. The  cholesterol-containing fractions were 
Density gradient centrifugation 
- . ,  - 
eluted usually at  the void volume. These fractions were 
pooled and concentrated with PM 10 membranes (Ami- 
con) to a final volume of 1-2 ml. Further characterization 
was done by chemical assay, electron microscopy, density 
Ultracentrifugation was performed on a CsC1-gradient 
(density 1.05-1.35 g/ml) at 50,000 rpm in a Beckman 
SW-60 rotor for 68 hr. Eleven or 12 fractions were ob- 
tained by pipetting from the top. Absorbance at 280 nm 
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and total cholesterol content were measured in each frac- 
tion (39). 
Electrophoresis and immunodiffusion 
Electrophoretic separation was done on 1 % agarose 
gels according to Noble (40). For SDS-polyacrylamide gel 
electrophoresis, aliquots of the fractions were lyophilized 
and then mixed with Tris-HC1 (37.5 mM, pH 8.8) con- 
taining 2% SDS, 4% 2-mercaptoethanol, and 10% sucrose. 
After incubation for 2 hr at 50°C, protein subunits were 
separated in 1.5-mm vertical slab gels using 4-22.5% 
acrylamide concentrations (41). After fixing the gel for 
30 min in 20% (w/v) trichloracetic acid, the proteins 
were stained with Coomassie brilliant blue (G 250). Mo- 
lecular weights were estimated comparing with the low 
molecular weight calibration kit (Pharmacia Fine Chem- 
icals) (42). 
Ouchterlony immunodiffusion was performed in 1.5% 
agar (Difco) at 2OoC on glass plates (5 X 2 cm) for 48 
hr. Antisera against human serum, human albumin, a- 
and &lipoproteins were obtained from Behring (Mar- 
burg). Special antisera against cellular lipoproteins of liver 
(anti-LSP) and kidney (anti-KSP) were kindly provided 
by U. Behrens, Immunopathology Laboratory, VAM 
Center, Bronx, NY. The  antibodies against a- and 
/3-lipoproteins were identical with antibodies to apoHDL 
and apoLDL, respectively. The  manufacturer used LDL 
and HDL isolated by preparative ultracentrifugation from 
normal human plasma for immunization. Density intervals 
of 1.020-1.050and 1.063-1.21 g/ml were used for LDL 
and HDL antigen isolation, respectively. The  anti-HDL 
and anti-LDL antibodies did not react with lipoprotein- 
free plasma obtained by preparative ultracentrifugation 
of plasma at d > 1.25 g/ml. There was no cross-reactivity 
between anti-HDL with LDL and anti-LDL with HDL. 
For the preparation of antibodies against LSP and KSP, 
the antigens were isolated by Behrens from normal human 
liver and kidney that showed no significant histologic 
changes nor evidence of autolysis (43). Essentially the 
same method was used as described by McFarlane et al. 
(44). Tissue slices were washed free of blood in 0.25 M 
sucrose, adjusted to pH 8.0 with 1 M Tris, and then 
homogenized. The  homogenate was centrifuged at 
100,000 g in a SW-27 rotor and the supernatant was 
placed on a column of Sephadex G-100 (gel bed 90 X 2.5 
cm), previously equilibrated with 0.1 M Tris-HCL-0.2 M 
NaCl-1 mM EDTA, pH 8.0 (Tris/EDTA buffer). The  
first peak fractions were concentrated and then chro- 
matographed on a column of Sepharose 6 B using the 
Tris/EDTA buffer for equilibration and elution. The  
first peak material contained LSP and KSP and was fur- 
ther subjected to ultracentrifugal flotation in a CsCl gra- 
dient. 
LSP and KSP were recovered between the densities 
1.107 and 1.202 g/ml. Analysis by SDS-PAGE revealed 
that the relative mobilities of LSP and KSP components 
were similar and the molecular weights of the monomers 
ranged from 40,000 to 96,000. At least seven out of eight 
recognizable LSP and KSP bands had the same R f  value, 
with one of them corresponding to that of human al- 
bumin. Antisera against the purified antigens were pro- 
duced in rabbits and absorbed with lyophilized human 
plasma. Anti-LSP sera were tested by indirect immuno- 
fluorescence and immunoenzyme light microscopy on 
cryostat sections. They reacted with cell membranes not 
only of liver cells but also of smooth muscle fibers, thyroid 
follicles, intestine, spleen, kidney tubules, and glomeruli 
(43). Identical staining patterns were obtained with anti- 
KSP sera by Behrens and Paronetto (43). These findings 
of Behrens and Paronetto demonstrate the non-organ 
specificity of LSP and KSP. By immunodiffusion anti- 
LSP serum formed precipitin lines with LSP and KSP, 
as well as with SDS- or papain-solubilized isolated liver 
cell membranes (43). No reaction of anti-LSP and anti- 
KSP sera was seen by immunodiffusion against human 
albumin or total human plasma. These observations were 
made with the anti-LSP and anti-KSP sera used in this 
study. 
RESULTS 
Normal subjects 
After gel filtration on the Bio-Gel A-5 m column, urines 
of normal subjects showed similar elution patterns. The  
characteristic profile illustrated in Fig. 1 shows that the 
major portion of the cholesterol recovered from urine 
was eluted in the void volume. The  total amount of uri- 
nary cholesterol in the 24-hr samples and the percentage 
081 0 2 1  
0 6 1  9015. 
IO 20 30 LO 50 
FRACTIONS 
Fig. 1. Gel chromatographic elution pattern of a concentrated U~~MI-Y 
sample from a normal subject on Bio-Gel A-5m. Column size 120 X 2.0 
cm. Individual points represent values of cholesterol (0 - 0, mg/ 
10-ml fraction) and the absorbance at 280 nm (0 - 0). 
Jiingst et al. Urinary cholesterol 657 
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TABLE 1 .  Clinical data and relative percentage of cholesterol in the void volume 
fractions after gel chromatography on the Bic-Gel A-5m column in normal subjects 
Serum Serum Urinary Urinary % Cholesterol 
Subject Protein Creatinine Protein Cholesterol in Void Volume 
gldl 
7.8 
8.3 
7.4 
7.9 
7.5 
8.2 
7.2 
7.3 
7.8 
mgldl 
0.8 
0.7 
1 .o 
0.6 
0.8 
0.9 
1 .O 
0.6 
1 .o 
mgi24 hr 
65 
50 
42 
83 
92 
34 
76 
52 
67 
mg124 hi 
0.6 
0.9 
0.4 
1.8 
2.1 
0.8 
0.7 
0.8 
1.3 
84.0 
96.0 
93.4 
95.3 
86.2 
91.7 
94.6 
87.5 
98.8 
of the recovered cholesterol in the void volume fractions 
is given in Table 1. Between 84 and 99% of the cholesterol 
appeared in the void volume, indicating that it was as- 
sociated with a macromolecular complex of more than 
5 X lo6 daltons. Only a minor portion of the cholesterol 
was found in the included volume of the column. Al- 
though it is possible that small amounts of HDL were 
present in these fractions, immunodiffusion against anti- 
a- and &lipoproteins and agarose-electrophoresis failed 
to demonstrate these lipoproteins. 
Patients 
In 8 out of 12 urines of patients with benign diseases 
of the kidneys and the urogenital tract a comparable elu- 
tion pattern as in normal subjects (Fig. 1) was seen after 
gel filtration on the Bio-Gel A-5 m column. In these cases 
84 to 98% of the cholesterol was found in the void volume 
fractions after gel chromatography (Table 2). 
However, in one patient with a renal cyst and in three 
patients with the nephrotic syndrome, only 44 to 75% 
of the fractionated urinary cholesterol was eluted in the 
void volume (Table 2). Measurements of cholesterol in 
the single fractions revealed two (Fig. 2) or three (Fig. 
3) cholesterol peaks. In the second peak immunodiffusion 
showed precipitin lines against anti-apoLDL and in the 
third peak precipitin lines against anti-apoHDL were seen 
(Fig. 4 and Fig. 5). 
In patients with malignant disease of the kidneys or 
the urogenital tract, 44 to 100% of the urinary cholesterol 
was found in the void volume fractions (Table 3). In 
single cases, HDL and LDL were detected in the lower 
molecular weight fractions as judged by agarose electro- 
phoresis and immunodiffusion against anti-apoLDL and 
anti-apoHDL. These results demonstrate that urinary 
cholesterol is mainly excreted as a macromolecular com- 
plex in normal subjects, as well as in patients with benign 
or malignant diseases of the kidneys or the urogenital 
tract. 
TABLE 2. Clinical data and relative percentage of urinary cholesterol in the void volume fractions 
after gel chromatography on the Bio-Gel A-5m column in patients with benign 
diseases of the kidneys and the urogenital tract 
Serum Serum Urinary Urinary Cholesterol % 
Diagnosis Subject Protein Creatinine Protein Cholesterol in Void Volume 
Urolithiasis 
Renal cyst 
Nephrotic syndrome 
Glomerular nephritis 
Lupus erythematosus 
Diabetic glomerular 
Glomerular nephritis 
Glomerular nephritis 
Prostatic adenoma 
sclerosis 
J 
K 
L 
M 
N 
0 
P 
Q 
R 
S 
T 
U 
gld l  
7.5 
8.1 
7.7 
8.3 
7.2 
5.5 
5.2 
5.8 
5.9 
5.5 
8.5 
7.9 
mgldl g124 hr 
0.9 0.18 
1 . 1  0.14 
0.8 0.32 
2.2 0.41 
1 . 1  0.35 
1.4 8.2 
2.5 12.1 
2.0 4.3 
1.2 5.5 
1 . 1  3.7 
0.9 0.22 
0.8 0.34 
mgi24 hr 
3.5 
0.7 
5.4 
1.8 
7.3 
59.0 
81.0 
18.1 
5.9 
14.7 
3.4 
11.5 
85.2 
98.4 
87.3 
88.6 
68.1 
58.3 
44.2 
75.2 
98.6 
92.3 
84.3 
95.8 
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Fig. 2. Gel chromatographic  elution  pattern  of  a  concentrated  urinary 
sample  from  a  patient with a  nephrotic  syndrome on Bio-Gel A-5m. 
Column size 120 X 2.0 cm.  Individual  points  represent values of cho- 
lesterol (0 - 0, mg/lO-ml fraction) and the  absorbance  at  280 
nm (0 - 0). 
Characterization of the  macromolecular 
urinary complex 
Macroscopically, the isolated cholesterol-containing 
complex in the void  volume  fractions was turbid, appeared 
to be labile, and showed a tendency to  aggregate  after 
storage at 4OC for several  days. In regard  to  the xclusion 
limit of the Bio-Gel A-5 m column, the estimated mo- 
lecular weight  of this complex was above 5 X l O6 daltons. 
Electron  microscopy  showed lipoprotein-like particles 
with diameters ranging from 300 to 700 A (Fig. 6). The 
chemical analysis revealed the presence of protein, tri- 
glycerides, and phospholipids in addition to cholesterol. 
The compositions (%) of  these constituents (ranges and 
median  values) are illustrated in Table 4. Fractionation 
of the phospholipids by two-dimensional thin-layer chro- 
IO 20 30 LO 50 
FRACTIONS 
Fig. 3. Gel chromatographic  elution  pattern of a  concentrated  urinary 
sample  from  a  patient with a  nephrotic  syndrome  on Bio-Gel A-5m. 
Column size 120 X 2.0 cm. Individual  points  represent values of  cho- 
lesterol (0 - 0, mg/lO-ml fraction) and  the  absorbance  at 280 
nm (0 - 0). 
Fig. 4. Immunodiffusion of the isolated  protein-lipid  complex which 
was eluted in the second  peak  fraction (Fig. 3) (1, 3. 5 ,  7) against  anti- 
apoLDL  (2, 4, 6). 
matography (TLC) showed ethanolamine phospho- 
glycerides, phosphatidylcholine, sphingomyelin, and 
phosphatidylserine as the main components (Table 5). 
Electrophoretic separation of the macromolecular 
complex on 1% agarose gels was not possible, since all 
the material remained at the origin. Density ultracen- 
trifugation in a CsCl gradient showed the cholesterol- 
containing complex between the densities 1.1 and 1.3 
g/ml (Fig. 7). The protein subunit constituents of the 
complex were studied by SDS-polyacrylamide gel elec- 
trophoresis. In a molecular weight range of 14,400  to 
87,500, up to 17 protein subunits were separated (Fig. 
8). Immunodiffusion studies showed no precipitin lines 
against anti-human-apoHDL and anti-human-apoLDL but 
in about  40% against anti-human albumin. However, im- 
munodiffusion of the macromolecular complex against 
Fig. 5. Immunodiffusion of the isolated  protein-lipid  complex which 
was eluted in the  third  peak  fraction  (Fig. 3), (2, 4, 6, 7) against  anti- 
apoHDL (1, 3. 5). 
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TABLE 3. Clinical data and relative percentage of urinary cholesterol in the void volume fractions 
after gel chromatography on  the Bio-Gel A-5m column in patients with malignant 
diseases of the kidneys and the urogenital tract 
Serum  Serum Urinary Urinary Cholesterol o/c 
Diagnosis Subject Protein Creatinine Protein Cholesterol in Void  Volume 
gld l  mgldl g124 hr 1ng124 hr 
Carcinoma of the AA 6.9 1 .O 0.35 2.5 86.2 
kidney BB 7.1  0.8 0.2 1 0.9  91.5 
cc 7.8 1.1 0.42 15.5 97.3 
Carcinoma of the DD 6.8 0.7  0.3 1 0.8 100.0 
bladder EE 7.4 1.1 0.27 12.7 76.1 
Carcinoma of the FF 8.1  0.7 0.16  3.8 100.0 
prostate GG 8.5 1.4 0.15 1.1 94.6 
HH 7.1  1 .o 0.29 2.7 75.3 
I1 7.8 0.6 0.30  2.2 44.3 
anti-LSP and anti-KSP revealed single precipitin lines, 
suggesting that this  macromolecular  protein-lipid  complex 
is  of cellular origin (Fig. 9). 
1000 A -
Fig. 6. Electron micrograph of the isolated macromolecular urinary 
protein-lipid complex negative stained with  uranium acetate and ob- 
served in a Siemens 10 1 electron microscope (X 120,000). 
DISCUSSION 
Cholesterol in the  urine of normal male and female 
individuals is mainly associated with a macromolecular 
protein-lipid complex  which appears to be of cellular or- 
igin.  Only  small amounts of cholesterol could be removed 
by filtration using Selecta filter 1 1 17 1/2, presumably 
reflecting the presence of  small numbers of intact cells, 
such  as  leucocytes and erythrocytes, and of larger cellular 
debris. During the whole fractionation procedure  a con- 
siderable loss of lipids occurred, especially at the two 
ultrafiltration steps. This might be due to some adherence 
of the protein-lipid complex to  the PM 10 membrane. 
In addition, some  of the lipid was lost directly through 
the membrane, most likely as a consequence of delipi- 
dation. Recovery studies for cholesterol in single urinary 
specimens  showed a total loss of urinary cholesterol be- 
tween 30 and 50% at  the  end of the fractionation pro- 
cedures. Most of the cholesterol was lost during ultrafil- 
tration; the recovery after gel chromatography was nearly 
95-100%. The form of the cholesterol lost during frac- 
tionation has not been investigated. However, it seems 
impossible that cholesterol could pass the PM 10 mem- 
brane in association  with an intact lipoprotein. I t  might 
be present in the form of free molecules  which originate 
from the macromolecular protein-lipid complex. 
Plasma lipoproteins were not detected in the normal 
urinary samples investigated. However, a minor portion 
of the recovered urinary cholesterol was eluted in the 
lower  molecular  weight range  after gel filtration on the 
Bio-Gel A-5 m column. This might be caused by small 
amounts of HDL undetectable by Ouchterlony immu- 
nodiffusion. These suggestions were supported by the 
findings of Segal and co-workers (45) who detected apo- 
proteins of HDL in highly concentrated urine of normal 
subjects.  However, their study  showed neither apoprotein 
660 Journal of Lipid Research Volume 25, 1984 
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TABLE 4. Relative composition of lipid and protein in the macromolecular 
complex isolated from urinary samples of normal subjects and patients 
with benign or malignant diseases of the kidneys or the urogenital 
tract (range and median values) 
Normal Subjects Benign Diseases Malignant Disease 
(5Y (7) 15) 
a 
Triglycerides 11.4-24.8 (16.3) 9.8-21.7 (14.3) 7.4-18.0 (11.8) 
Phospholipids 19.5-38.9 (29.5) 12.7-31.1 (19.8) 13.6-29.7 (20.9) 
Cholesterol 3.1-14.5 (8.2) 4.2-15.3 (9.1) 3.7-12.4 (7.5) 
Protein 39.6-53.1 (46.0) 45.8-68.2 (56.8) 44.3-72.5 (59.8) 
a Number of subjects in each category in parentheses. 
B nor apoprotein E in the urine, suggesting that VLDL 
and LDL are not excreted in the urine of normal subjects. 
In accordance with these observations we were not able 
to detect LDL or VLDL in normal urine. In patients 
with benign or malignant diseases of the kidneys or the 
urogenital tract, usually most of the excreted urinary 
cholesterol could be found in the void volume fractions 
after gel filtration. These findings show that hyperex- 
cretion of urinary cholesterol in these diseases is caused 
mainly by increasing amounts of the macromolecular 
protein-lipid complex in urine. 
Only in single samples with elevated urinary choles- 
terol, especially in patients with the nephrotic syndrome, 
were major portions of urinary cholesterol eluted in the 
lower molecular weight fractions after gel chromatog- 
raphy on the Bio-Gel A-5 m column. In these fractions 
HDL and LDL could be detected by agarose electro- 
phoresis and immunodiffusion against specific antisera. 
The results, for the nephrotic syndrome urine, were in 
accordance with studies performed by Kashyap and co- 
workers (31) who found HDL as well as LDL in concen- 
trated urinary samples of several patients with the ne- 
phrotic syndrome. Using double immunodiffusion and 
lipoprotein electrophoresis, they detected HDL in the 
urine of nine nephrotic patients investigated. No plasma 
lipoproteins were found in urine of normal subjects or 
patients with primary hyperlipoproteinemia and normal 
renal function. LDL was detected in the urine of only 
two patients with the nephrotic syndrome, most likely 
due to its higher molecular weight in comparison to HDL. 
However, our findings show that in the nephrotic syn- 
drome also, a considerable portion of the total urinary 
cholesterol is associated with a macromolecular proteo- 
lipid which was eluted in the void volume fractions after 
gel filtration on the Bio-Gel A-5 m column, in contrast 
to HDL and LDL. This macromolecular protein-lipid 
complex had an opalescent appearance similar to the light 
particulate fraction isolated by ultracentrifugation from 
normal urine by Cenedella and Belis (29). 
However, the electrophoretic profile of proteins re- 
covered from their 100,000 g (60 min) urine pellet was 
slightly different from the electrophoretic separations in 
this study. This might be due to the different methods 
of isolation, ultrafiltration, and gel chromatography versus 
ultracentrifugation. The isolated urinar protein-lipid 
electron microscopy, and the particles showed a globular 
shape. The chemical assays were in accordance with a 
proteolipid which seemed to be partially delipidated in 
regard to the broad density range of 1.1 to 1.3 g/ml. 
Albumin could be identified in 40% of the samples as 
the only plasma protein of the isolated urinary protein- 
lipid complex and might be considered as a nonspecific 
contaminant. The nature of the other protein components 
is unknown although there is some evidence that they 
could be of cellular origin. Cellular protein-lipid com- 
complex had a diameter of 300 to 700 x as judged by 
TABLE 5. Relative composition of phospholipids in the macromolecular complex isolated from 
urinary samples of normal subjects and patients with benign or malignant diseases 
of the kidneys or the urogenital tract (range and median values) 
Normal Subjects Benign Diseases Malignant Diseases 
(5)n (7) ( 5 )  
Ethanolamine glycerophospholipids 22.4-42.1 (31.5) 19.8-38.1 (27.4) 24.1-41.5 (33.4) 
Phosphatidylcholine 21.3-36.4 (28.1) 28.3-38.9 (34.6) 19.8-33.7 (26.2) 
Sphingomyelin 16.6-26.2 (19.6) 12.1-23.7 (15.3) 13.3-24.1 (17.6) 
Phosphatidylserine 15.9-26.1 (20.8) 17.8-27.2 (22.7) 16.3-26.1 (22.8) 
a Number of subjects in each category in parentheses. 
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Fig. 7. Density ultracentrifugation in a CsCl gradient of the isolated 
macromolecular urinary protein-lipid complex in a Beckman SW-60 
rotor (68 hr). Individual points represent values of cholesterol 
(0 - 0, mg/fraction) and the absorbance at 280 nm (0 - 0). 
plexes have been isolated from the liver and recently 
from the kidney (43,46). They were found in the 150,000 
g supernatant of  liver or kidney homogenates, but im- 
munofluorescent studies indicate that they were derived 
from cell membranes (43,  44). After gel filtration on 
1 2 3 4 
Fig. 8. SDS-PACE of the isolated macromolecular urinary protein- 
lipid complex in 1.5-mm vertical slab gels using 4-22.5% acrylamide 
concentrations (lanes 1, 2, 3). Standard proteins phosphorylase b 
(94.000), albumin (67.000), ovalbumin (43,000), carbonic anhydrase 
(30,000). trypsin inhibitor (20,100). and a-lactalbumin (14.000) were 
used (lane 4). 
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Fig. 9. Immunodiffusion of the isolated macromolecular urinary pro- 
tein-lipid complex (1, 3. 5, 7) in 1.58  agar (Difco) at 2OoC for 48 hr 
against  anti-KSP (2, 4) and anti-LSP (6). 
Sepharose 6B columns,  these  protein-lipid  complexes  were 
eluted in the void volume fractions, suggesting a high 
molecular  weight above 5 X lo6 daltons (43,  44). SDS- 
PAGE  of the associated proteins separated  up to 13 sub- 
units in a molecular weight range between 30,000 and 
90,000 daltons. Since there were similarities between 
these  cellular  proteolipids and  the isolated urinary protein- 
lipid complex, further identification by immunodiffusion 
studies was undertaken. Anti-LSP and anti-KSP sera were 
provided by Behrens and  Paronetto (43). These antisera 
did not react with  plasma lipoproteins or other plasma 
proteins but showed precipitin lines against cytosolic pro- 
teins  in  liver or kidney  cells  which are not associated  with 
lipids (43). However, they reacted with  cell membranes 
not only  of  liver or kidney cells but also  of smooth muscle 
fibers, thyroid follicles, intestine, and spleen. No studies 
were performed against tissue  of the bladder or other 
parts of the urinary tract. In our study immunodiffusion 
of these antisera against the isolated macromolecular uri- 
nary proteolipid revealed single precipitin lines which 
support the view that cells were the source of this complex. 
In  kidney  disease we suppose that most  of this urinary 
complex is of renal origin. In diseases  of the bladder it 
is much more likely that this organ is the major source 
of urinary cholesterol. In regard to  the immunofluores- 
cent studies, the urinary protein-lipid complex might be 
a fragment of a plasma membrane. This is supported by 
the findings  of Cenedella and Belis (29). These  authors 
described a high  activity  of  5'-nucleotidase, a  marker en- 
zyme for plasma membranes, in their light particulate 
cholesterol-containing fraction. 
In  conclusion, the isolated macromolecular cholesterol- 
containing urinary complex showed  many characteristics 
of  membrane-associated protein-lipid particles of the hu- 
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man kidney and even the liver and is most likely a frag- 
ment of the plasma membrane.l 
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